Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791076 · ClinicalTrials.gov registry record · Phase 2
The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00791076: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT00791076 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791076, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this research is to see if pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas and that works to control the amount of glucose that the liver makes, will reduce the amount of insulin required for people who must take insulin to maintain their normal blood glucose level.
Interventions
- DRUG Placebo
- DRUG Pancreatic Polypeptide (PP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791076
The ClinicalTrials.gov registry entry for NCT00791076 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00791076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791076 about?
NCT00791076 is a clinical study titled "The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients". The goal of this research is to see if pancreatic polypeptide (PP), a hormone that is naturally produced by the pancreas and that works to control the amount of glucose that the liver makes, will reduce the amount of insulin required for people who must take insulin to maintain their normal blood gl...
What is the current status of trial NCT00791076?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2007-10. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00791076?
The interventions under investigation include: Placebo (DRUG), Pancreatic Polypeptide (PP) (DRUG).
Who is sponsoring clinical trial NCT00791076?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.